Introduction
============

HIV/AIDS has continued as a leading public health problem globally. Particularly, low income countries such as sub-Saharan African countries are challenged with a widespread of the virus and socio-economic crises due to the disease ([@R1], [@R2]). Globally, in the previous era, many efforts had been made to fight against the worldwide HIV epidemic ([@R3], [@R4]). Accessibility of the ART treatment program had scaled-up ([@R3]). Hence, almost 10 million people had received the treatment by the end of 2012 ([@R5]). Accordingly, the rate of new infections and HIV/AIDS related morbidity and mortality declined significantly ([@R3], [@R4]). The scaled-up accessibility of ART treatment saved around 2.5 million lives from HIV-related deaths in developing countries, since 1995 ([@R2]).

ART treatment can suppress the viral replication, enhance immunological status, can reduce HIV transmission to uninfected people, and increase patients\' life expectancy ([@R6]). With the availability of free ART treatment, the cost of ART, and related care is no longer adequate for treatment success and HIV-related mortality reduction ([@R7], [@R8]). Although efforts such as improving patients\' awareness to seek treatment and when to initiate therapy, supporting continuity care, promoting and ensuring high ART adherence rate are vitally important ([@R9]).

The level of adherence to ART can vary based on population context, and moreover, it is affected by individual, service, and therapy-related factors such as substance abuse, psychiatric problems, inability to disclose HIV status, lack of psychosocial support, stigma, drug side effect, pill burden, poor quality service delivery, and unexplained treatment cost ([@R10], [@R11]).

In Ethiopia, HIV epidemic is continuing to be a threat to the lives of many productive age groups ([@R12]). In 2007, it was estimated that 977,394 people lived with the virus, and this would result in a total of 71,902 HIV-related deaths. In the same year, the prevalence of HIV in Ethiopia was estimated to be 2.1% ([@R12]). However, the national HIV prevalence in 2014 was 1.14% ([@R13]). The advent of ART treatment in Ethiopia improved the quality of life for HIV-positive people and increased their life expectancy. Since Ethiopia\'s ART program began in 2003, a total number of 210,637 people started treatment in 481 facilities throughout the country. ART service expansion was recent and fast from only four facilities in 2003 to 481 in 2009 ([@R14]).

The ART adherence is now well understood as the most important determinant ([@R15]), and it is the 'Achilles heel' of ART treatment success ([@R16], [@R17]). Poor adherence can lead to preventable HIV-related deaths. Moreover, it increases the risk of the emerging-drug resistant HIV strains ([@R16], [@R18]). Hence, educating and sustaining ART treatment adherence to the HIV positive individual is the important component which needs public health efforts ([@R19]). Due to many factors, a high number of HIV positive individuals are still dropping out from their treatment follow-up ([@R5], [@R20]).

A recent study has shown that the emergence of drug-resistant HIV strains in 'ART-naive people' is increasing ([@R21]). According to a World Health Organization (WHO) survey study in 12 developing countries in 2012, the HIV drug resistance rate among people starting ART ranged from 4.8% in 2007 to 6,8% in 2010 ([@R22]). Hence, "attention to and strengthening of adherence throughout the entire course of ART comprises an essential part of any successful treatment programme and should be built into the country-specific program" ([@R20]). Although the magnitude of HIV at the study area was not known, the number of people who were registered to get HIV care and treatment was increasing, and there is limited information about the ART adherence level of people living with HIV/AIDS. Moreover, most peoples living in the study are pastoral and agro-pastorals. Hence, many factors might hinder them to adhere to their ART medications. Currently, the prevalence of HIV is increasing in the rural community. However, regional and the national HIV/AIDS prevention and control programme is unable to reach to investigate the magnitude of the disease, health service quality, individuals\' ART adherence level, and their social and behavioural factors that hinder their ART treatment seeking behaviour. Many kinds of research are conducted in well-established towns where most aware individuals about HIV/AIDS live. Therefore, this study was aimed to assess the level of adherence to ART treatment and its associated factors in Hara Town and its surroundings, North-Eastern Ethiopia.

Methods and Materials
=====================

**Settings**: The study was done in the ART Unit of Hara Health Center. Hara is in the eastern part of the Amhara Region in North Wollo Zone. It is located at 383km from the regional capital city, Bahir Dar, and 543km from Addis Ababa. The town had a total population of 28,096, (14188 males and 13,908 females). There was one ART clinic, 7 health posts, and 5 private clinics in the town. During this study piloted, there were a total of 454 HIV positive people who were on ART treatment follow-up. Four hundred eighteen patients were enrolled in this study.

**Study design and period**: An institutional facility based cross-sectional study was conducted from April to May 2017 to assess the level of adherence to ART and its associated factors among HIV positive individual in Hara Town and its surroundings, North-Eastern Ethiopia.

**Study population and eligibility criteria**: All HIV positive adults (≥18 years old) who were currently on Highly Active Antiretroviral Therapy (HAART) follow-up at least for 3 months and had no difficulty to communicate were enrolled in this study. However, those patients who were seriously ill during data collection, and those who were under 18 years of age were excluded.

**Sample size**: Single population proportion formula was used to calculate the sample size. We considered the proportion (P) of good adherence from a previous study 85.3% ([@R10]), the margin of error 5% at 95% confidence interval. Therefore, the final sample size was 193. However, there were a total of 454 adults who were on ART treatment follow-up in the study setting (ART-clinic); hence, all eligible study subjects were included.

**Data collection procedures**: A structured questionnaire was used as a data collection tool. We adapted the questionnaire partly from the AIDS Clinical Trial Group (ACTG) ([@R23]), adherence baseline and follow-up questionnaires. Pilot study was conducted on 5% of the total sample size at Kobo Health Center to check the validity of the questionnaire. The questionnaire includes information on socio-demographics, individual characteristics, and health and economic status of the respondents. The English version of the questionnaire was translated into local language (Amharic) for ease of understansing and it was translated back into the English language to check content validity. Two diploma nurses performed the interview and the data collection using the face-to-face interview method. Training was given to data collectors about the objectives of the study, and how they could approach the patients to obtain their confidentiality. Written and verbal consent was obtained from the study participants after the objectives of the study were explained. Patients\' clinical data such as WHO clinical stage and the CD4 counts were retrieved from their medical record registration book at the ART clinic. An antiretroviral therapy adherence level was calculated based on the patients\' report of seven days recall of missed doses before the interview date.

**Data analysis**: All the collected data were entered into EPI-Data 3.1 statistical software to code and edit errors, and then transferred into SPSS version 20.0 for analysis. The data were calculated and presented using descriptive statistics. Multivariate logistic regression analysis was performed to identify and check the associated risk factors to adherence. Odds ratio with 95%CI was calculated, and independent variables with *p*-values of less than 0.05 in multivariate logistic regression analysis were considered significantly associated with adherence.

Definition of operational term
------------------------------

**Adherence**: Adherence is defined as **good** if it is ≥95% (\<2 doses of 30 doses or \<30 doss of 60 doses is missed) as documented by ART healthcare provider. It is **poor** if it is between 85--94% (3--5 doses of 30 doses or 3--9 doses of 60 doses is missed) as documented by the ART healthcare provider.

**Ethical consideration**: Ethical approval letter was obtained from the institutional Research Review Committee of Health Sciences Faculty, Woldia University (No: 18/FHS/RERC/2017). Official permission letter was obtained from North Wollo Zone Health Department and Hara Health Center. The objective of the study was explained to all study subjects to obtain their verbal or written consent before the interview. Participants were informed that they had the full right to discontinue participating in the study if they felt discomfort. They were also assured that all the data provided by them would be kept confidential. In addition, no personal identifiers were used.

Results
=======

**Socio-demographic characteristics**: Out of a total of 454 study participants, 418 people living with HIV and currently on ART follow-up were enrolled in the analysis. The response rate was 92.1%. Thirty-six cases were excluded because they were less than 18 years old. Of the total 418 participants, 246 (58.9%) were females. The mean age of the study participants was 38.17years while 36.6% of them were between the ages of 25--34 years. Of the total, 35.9% were married. The majority, (69.4%) of the study participants were illiterate. Two hundred twenty-seven (54.3%) of them were farmers. The majority, 332 (79.4%) did not get support from their family members to take their medication timely ([Table 1](#T1){ref-type="table"}).

###### 

Socio-demographic characteristics of the study participants in Hara Town and its surroundings, April to May 2017 (n = 418)

                                                      Attributes                             N     \%
  --------------------------------------------------- -------------------------------------- ----- ------
  **Sex**                                             Male                                   172   41.1
                                                      Female                                 246   58.9
  **Age (year)**                                      18--24                                 22    5.3
                                                      25--34                                 153   36.6
                                                      35--44                                 140   33.5
                                                      ≥45                                    103   24.6
  **Marital status**                                  Married                                150   35.9
                                                      Divorced/ separated                    185   44.3
                                                      Single                                 67    16
                                                      Widowed                                16    3.8
  **Educational status**                              Illiterate                             290   69.4
                                                      Can read and write                     54    12.9
                                                      Elementary                             61    14.6
                                                      Secondary school & above               13    3.1
  **Residence**                                       Urban                                  278   66.5
                                                      Rural                                  140   33.5
  **Religion**                                        Orthodox                               58    13.9
                                                      Muslim                                 360   86.1
  **Occupation**                                      Merchant                               38    9.1
                                                      Housewife                              99    23.7
                                                      Farmer                                 227   54.3
                                                      Government employ                      16    3.8
                                                      Other[\*](#TF2){ref-type="table-fn"}   38    9.1
  **Distance from the health facility**               \<10km                                 268   64.1
                                                      ≥10km                                  150   35.9
  **Monthly income**[\#](#TF1){ref-type="table-fn"}   ≤500                                   287   68.7
                                                      501--999                               96    22.9
                                                      ≥1000                                  35    8.4
  **Getting support**                                 Yes                                    86    20.6
                                                      No                                     332   79.4

Exchange rate 1USD = 27.22 Ethiopian Birr;

students, daily laborer

**Clinical and Behavioural Characteristics of the respondents**: Two hundred (47.8%) of the participants were at WHO clinical stage III. Two hundred thirty-six (56.5%) of them had a baseline CD4 count between 200--499cells/mm^3^ while 61.7% had a CD4 count between 200--499 during the antiretroviral treatment initiation time, and 55% had the CD4 count of ≥500 cells/mm^3^ during the interview. Three hundred ninety-two (93.8%) of the respondents reported that they experienced drug side effect to ARV (antiretroviral) drugs; while, 93 (22.2%) had histories of opportunistic infections. Of the total respondents, 361 (86.4%) did not disclose their HIV status to their relatives ([Table 2](#T2){ref-type="table"}).

###### 

Clinical and behavioural characteristics of the study participants in Hara Town and its surroundings, April to May 2017 (n = 418)

  ----------------------------------------------------------------------------
  Attributes                                                     N      \%
  -------------------------------------------------- ----------- ------ ------
  **WHO clinical stage at the start of ART**         Stage I     51     12.2

                                                     Stage II    108    25.8

                                                     Stage III   200    47.8

                                                     Stage IV    59     14.1

  **Baseline CD4 count**                             \<200       74     17.7

                                                     200--499    236    56.5

                                                     ≥500        108    25.8

  **CD4 count at the start of treatment**            \<200       73     17.5

                                                     200--499    258    61.7

                                                     ≥500        87     20.8

  **Current CD4 count**                              \<500       188    45

                                                     ≥500        230    55

  **Encountered drug side effect in relation to**\   Yes         392    93.8
  **ART**                                                               

  No                                                 26          6.2    

  **History of opportunistic infections (OIs)**      Yes         93     22.2

                                                     No          325    77.8

  **Using memory aids as time reminder to take**\    Yes         153    36.6
  **medication timely**                                                 

  No                                                 265         63.4   

  **History of using an active substance like**\     Yes         29     6.9
  **alcohol**                                                           

  No                                                 389         93.1   

  **Disclose HIV status for families**               Yes         57     13.6

                                                     No          361    86.4
  ----------------------------------------------------------------------------

The adherence measurement was calculated based on the respondents\' self-report. In this study, of the total participants, only 71.8% (95% CI: 70.8%-74.4%) reported to have an adherence level of ≥95% in seven days before the interview. The adherence level of ART in the previous three days prior to the data collection date was 82.5%. The majority of the respondents with poor adherence, 63 (53.4%) had reported that they forget to take their medication timely ([Table 3](#T3){ref-type="table"}).

###### 

Study participants\' adherence to ARV drugs at Hara Town and its surroundings, Ethiopia, April to May 2017 (n =418)

  ------------------------------------------------------------------------------------------
  *Attributes*                                                                 N      \%
  ----------------------------------------------------- ---------------------- ------ ------
  Taking other medication in addition to ARV drugs      Yes                    29     6.9

                                                        No                     389    93.1

  How did you take ARV drug doses in the last 7\        Missed                 118    28.2
  days                                                                                

  Not missed                                            300                    71.8   

  Number of ARV drug doses missed in the last 7\        ≤ 2 doses              64     54.2
  days                                                                                

  ≥ 3 doses                                             54                     45.8   

  Number of ARV drugs doses missed in the last 3 days   ≤2 doses               41     56.2

                                                        ≤ 3 doses              32     43.8

  Reasons for nonadherence to ART                       Illness                13     11.0

                                                        Transportation         26     22.0

                                                        Refusal to take the\   16     13.6
                                                        drugs                         

                                                        Forgetfulness          63     53.4
  ------------------------------------------------------------------------------------------

**Factors associated with adherence to ART**: Different socio-demographic and adherence related variables were entered in stepwise regression. Crude analysis showed that residence, distance from the health facility, disclosure of HIV status to families, encounter of drug side effect, having history of opportunistic infections, and current CD4 count were negatively associated with adherence to ARV drugs (p\<0.05). In multivariate logistic regression analysis, only disclosure HIV status to families (AOR: 0.12, 95% CI: 0.05--0.58; P\<0.001) and encounter of drug side effect (AOR: 2.69, 95% CI: 1.27--5.05; p\<0.001) were factors that negatively affected the respondents\' adherence to ARV drugs ([Table 4](#T4){ref-type="table"}).

###### 

Bivariate and multivariate analysis showing factors associated with adherence to ARV drugs in Hara Town and its surroundings, April to May 2017 (n = 418)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    Adherence to ARV drugs                                                                                                            
  -------------------------------------- ---------- ------------------------ ---------------------------------------------------- --------------------------------------------------- ----------------------------------------------------
  Disclose HIV status for families       Yes        38(32.2)                 19(6.3)                                              1                                                   1

                                         No         80(67.8)                 281(93.7)                                            0.12(0.04--0.37)[\*](#TF3){ref-type="table-fn"}     0.12(0.05--0.58) [\*\*](#TF4){ref-type="table-fn"}

  Residence of respondents               Rural      57(48.3)                 83(27.7)                                             1                                                   

                                         Urban      61(51.7)                 217(72.3)                                            3.58 (2.15--5.95) [\*](#TF3){ref-type="table-fn"}   

  Distance from the health facility      \<10Km     57(48.3)                 211 (70.3)                                           1                                                   

                                         ≥10Km      61(51.7)                 89(29.7)                                             3.67(2.18--6.18)[\*](#TF3){ref-type="table-fn"}     

  Encountered drug side effects in\      Yes        102(86.4)                290(96.7)                                            1                                                   1
  relation to ARV                                                                                                                                                                     

  No                                     16(13.6)   10(3.3)                  2.78 (1.86--4.17) [\*](#TF3){ref-type="table-fn"}    2.69(1.27--5.05)[\*\*](#TF4){ref-type="table-fn"}   

  History of opportunistic infections\   Yes        26(22.0)                 67 (22.3 )                                           1                                                   
  (OIs)                                                                                                                                                                               

  No                                     92(78.0)   233(77.7)                3.29 (2.09--5.198) [\*](#TF3){ref-type="table-fn"}                                                       

  Current CD4 count                      \<500      38(32.2)                 150(50.0)                                            1                                                   

                                         ≥500       80(67.8)                 150(50.0)                                            3.60(1.51--8.58) [\*](#TF3){ref-type="table-fn"}    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

P\<0.05;

P\<0.001;

1=constant

Discussion
==========

This study assessed patients\' ART adherence level and the factors associated with their ART adherence in Hara Town and its surroundings, North-Eastern Ethiopia. The adherence rate was found to be 71.8% in the past seven days of respondents\' recall of missed doses. Our result was below the recommended level of good adherence. It must be (≥95%) to suppress the viral load for a long time ([@R8]), to bring the patients\' clinical improvement and increased pateint\'s CD4 count ([@R24], [@R25])

This finding revealed a very low adherence level as compared to similar studies in Ethiopia: Gondar (85.3%) ([@R10]), Addis Ababa (73.3%) ([@R26]), Harar and Dire Dawa (85%) ([@R27]), Debre Berhan (95.5%) ([@R28]), Gondar (82.7%) ([@R29]), Jimma (94.3%) ([@R30]), and Jimma (95%) ([@R31]). The possible reason for this might be due to the difference in socio-demographic characteristics of participants, and the service quality discrepancy. This result is also lower than other studies conducted in some African countries: Uganda (97%), Namibia (86.1%), and Cameron (76.7% males vs 90.84% females) ([@R24]). However, this figure was higher than the study conducted in Ghana, 62.2% ([@R32]), rural Zambia (59.9%) ([@R33]), Nigeria (70.8%) ([@R17]), and Botswana (54%) ([@R34]). The low adherence rate reported from the above studies might be due to different population characteristics, health service quality, study settings, and the adherence level measurements used.

In our study, the majority, 63(53.4%) of the respondents reported that forgetfulness was the reason for their nonadherence followed by the transportation problem to the ART-clinic 26 (22%). From predicted associated factors, only respondents who did not disclose their HIV status to their families were 88% less likely to adhere as compared to those who had disclosed their HIV status (AOR: 0.12, 95% CI: 0.05--0.58). A similar findings were reported from Harar and Dire Dawa, Ethiopia, showing that patients who did not disclose their HIV status to their families were 55% less likely to adhere to their medication than those who disclosed their HIV status (AOR: 0.45; 95% CI: 0.21--0.97) ([@R35]). This implies that there was still fear of stigma and discrimination to disclose their HIV status to their families.

In this finding, drug side effect was another factor which was associated with particpants\' adherence to their ART medication. Respondents who had not encountered drug side effect were 2.69 times more likely to adhere to their ART medication than those who had experienced drug side effect (AOR: 2.69, 95%CI: 1.27--5.05). Incomparable to this, another study conducted in Gondar, Ethiopia, reported that respondents with drug side effect were 70% less likely to adhere to ARV therapy than those who did not encounter drug side effect (AOR: 0.3, 95%CI: 0.2--0.5) ([@R10]). Another study which was done in the Kathmandu District, Nepal, reported that the odds of adherence among those who did not experience drug side effects were 4.88 times higher than those who reported experiencing drug side effects ([@R36]). The severity of drug side effects varies from mild to life threating condition. Therefore, instead of droping out their medication, it is recommended to get a consultation with the healthcare providers to manage the adverse consequence of the ARV drugs.

In this study, a very low ART adherence level was reported. Intervention measures to promote ART adherence in the study area should get attention. These include revising counseling policy to investigate patients\' drug side effect and health education programs to enable HIV positive individuals to disclose their HIV status to their families and to deal with drug side effects.
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